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UDP-glucose Dehydrogenase Polymorphisms from Patients
with Congenital Heart Valve Defects Disrupt Enzyme Stability
and Quaternary Assembly*□
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Background: UDP-glucose dehydrogenase (UGDH) polymorphisms were identified in a screen of candidate genes for heart
valve defects.
Results: Two individual mutants fail to rescue cardiac valve defects in UGDH-deleted zebrafish and have reduced stability in vitro.
Conclusion: UGDH loss of function mutations result in a subset of human congenital cardiac valve defects caused by reduced
enzyme activity during morphogenesis.
Significance: Screening these alleles could predict valve defects.
Cardiac valve defects are a common congenital heart malformation and a significant clinical problem. Defining molecular
factors in cardiac valve development has facilitated identification of underlying causes of valve malformation. Gene disruption in zebrafish revealed a critical role for UDP-glucose dehydrogenase (UGDH) in valve development, so this gene was
screened for polymorphisms in a patient population suffering
from cardiac valve defects. Two genetic substitutions were identified and predicted to encode missense mutations of arginine
141 to cysteine and glutamate 416 to aspartate, respectively.
Using a zebrafish model of defective heart valve formation
caused by morpholino oligonucleotide knockdown of UGDH,
transcripts encoding the UGDH R141C or E416D mutant
enzymes were unable to restore cardiac valve formation and
could only partially rescue cardiac edema. Characterization of
the mutant recombinant enzymes purified from Escherichia coli
revealed modest alterations in the enzymatic activity of the
mutants and a significant reduction in the half-life of enzyme
activity at 37 °C. This reduction in activity could be propagated
to the wild-type enzyme in a 1:1 mixed reaction. Furthermore,
the quaternary structure of both mutants, normally hexameric,
was destabilized to favor the dimeric species, and the intrinsic
thermal stability of the R141C mutant was highly compromised.
The results are consistent with the reduced function of both
missense mutations significantly reducing the ability of UGDH
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to provide precursors for cardiac cushion formation, which is
essential to subsequent valve formation. The identification of
these polymorphisms in patient populations will help identify
families genetically at risk for valve defects.

Congenital heart defects, approximately one-fourth of which
result from improper valve or septal formation (1), are a prevalent health concern (2). In many cases, the defects may be mild,
and patients are not diagnosed until later in life, or the early
defect is managed surgically but continues to require vigilant
health awareness. Several genetic mutations have been correlated with these conditions (3, 4), but only a few of the molecular factors critical for normal heart development in humans
have been well characterized.
Heart morphogenesis is a complex multistep process involving changes in expression of hundreds of different genes, as well
as input from physical stimuli during development (3, 4). Model
organisms such as zebrafish have been invaluable for delineation of important signaling molecules and receptors that modulate the necessary changes (5– 8). In addition to specific signals, cell surface and extracellular adhesive molecules such as
proteoglycans and glycosaminoglycans are essential for presentation of small molecules, local magnification of their potency,
and generation of the hydrodynamic cushions ultimately
needed for heart chamber and valve differentiation (3, 9, 10).
The roles of genes involved in synthesis of these diverse anionic
carbohydrate polymers have been defined by elegant genetic
studies in which pre-cardial tissue from lethal disruptions is
explanted and developmentally rescued with transduction of
the targeted gene (9, 11).
UDP-glucose dehydrogenase (UGDH)3 is one candidate
gene essential for development in frogs (12), fruit flies (13),
3

The abbreviations used are: UGDH, UDP-glucose dehydrogenase; MO, morpholino; AV, atrioventricular; hpf, h post-fertilization.
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nematodes (14), and mice (9, 15), shown in zebrafish to be critical specifically for cardiac valve formation (11). This enzyme
produces UDP-glucuronate, key sugar nucleotide precursor for
incorporation into the extracellular matrix glycosaminoglycan
hyaluronan (16), modification of lipophilic hormones for
enhanced solubilization and elimination (17), polymerization
of heparan sulfate and chondroitin sulfate chains, as well as
conversion to UDP-xylose to initiate proteoglycan production
(10). Studies in bacterial (18, 19), plant (20, 21), bovine (22), and
human (23) UGDH homologues show that all of them catalyze
two successive oxidations of the 6⬘ carbon to orchestrate the
same conversion of UDP-glucose to UDP-glucuronate (18 –23).
Notably, the enzyme is active in bacteria as a dimer (24),
although in mammals and higher eukaryotes such as plant,
nematode, fruit fly, and zebrafish, the enzyme purifies and
functions as a hexamer (23, 25). This structure is a trimeric
assembly of dimeric units (26), which are homologous to the
bacterial dimer, organized in a toroidal formation that has been
visualized by electron microscopy (25) and x-ray crystallography (see Fig. 1).
The structure has been solved for the human UGDH T131A
apo form (Protein Data Bank code 3ITK), as a ternary complex
with NAD⫹ cofactor and UDP-glucuronate product (Protein
Data Bank code 2QG4), as a ternary complex with NADH
cofactor and UDP-glucose substrate (Protein Data Bank code
2Q3E) (27), and for UGDH E161Q as a thiohemiacetal between
Cys-276 and the singly oxidized UDP-glucose, captured following the addition of NAD⫹ and UDP-glucose (Protein Data Bank
code 3KHU) (28). In a prior study, we used the human UGDH
model to identify residues likely to be critical for catalytic activity and/or binding of the substrate and cofactor, which we subsequently confirmed using site-directed mutagenesis and enzymology (23, 29).
In a previously described large scale sequencing experiment
using candidate genes essential for atrioventricular (AV) canal,
AV septum, and AV valve formation, three patients with mitral
valvar prolapse and mitral regurgitation were identified with
novel missense mutations in the UGDH gene from among 192
patients with clinically diagnosed AV septal defects (30). Two of
these individuals were heterozygous for a single nucleotide substitution that converted Arg-141 of UGDH to cysteine (R141C).
A third individual was heterozygous for a mutation that converted Glu-416 to aspartate (E416D). Neither of these mutations was found in a control group of 350 normal individuals
and inspection of sequence alignments showed that both residues are conserved in human, mouse, and zebrafish UGDH.
Based on the UGDH model, the relevant residues were located
unambiguously. Glu-416 is hydrogen-bonded to a water molecule that positions the UDP-glucose substrate (Fig. 1). Arg-141
is remote from the active site but relatively proximal to the
putative subunit association faces of the enzyme.
In this report, the human UGDH polymorphisms and one
additional mutation (I331N, also known as Jekyll (11)), previously noted to prevent cardiac valve development in zebrafish,
were recreated in eukaryotic expression systems and in purified
recombinant protein to determine the respective physiological
and biochemical effects of the mutations. We examined the
specific impact of UGDH mutants on AV valve development in
SEPTEMBER 21, 2012 • VOLUME 287 • NUMBER 39

FIGURE 1. Ribbon representation of UGDH and location of mutations
characterized in this study. The human hexameric enzyme is depicted from
the top to illustrate the overall structure, the position of the active sites containing the substrate UDP-glucose, and the reduced cofactor NADH shown in
ball and stick form, as well as residues Arg-141, Glu-416, and Ile-331, relative
to the docking interface for association of the dimers to form a hexamer.
Individual subunits are colored in dimeric pairs of dark and light blue, dark and
light green, and dark and light purple. Amino acid side chains implicated in
cardiac valve malformation are shown in space-filling form and colored gold.

zebrafish, the ability to rescue cardiac defects induced by the
loss of UGDH, and compared these outcomes with the effect of
mutations on steady state enzyme activity, quaternary structural assembly, and intrinsic stability of the protein. This comprehensive approach provided insights into the underlying
molecular causes of valve defects in patients with UGDH polymorphisms and revealed novel aspects of UGDH enzymatic
function.

EXPERIMENTAL PROCEDURES
In Situ Hybridization—Embryos were fixed in 4% formaldehyde, embedded in paraplast, and sectioned for in situ hybridization (10 –14 m). Labeled RNA probes were used to detect
cardiac tropomyosin I or UGDH mRNA expression by in situ
hybridization according to a previously described method (31).
Representative images were digitally captured to illustrate message expression relative to AV canal and outflow tract.
Cardiac Valve Morphogenesis and in Vivo Rescue of Cardiac
Edema in Zebrafish—Wild-type and transgenic (Tg(Tie2:
EGFP)s849) zebrafish were maintained under standard conditions (32). Two independent antisense morpholino oligonucleotides (MOs) were used to knock down Ugdh expression:
ugdh-ATG MO, which was previously described (11), and
ugdh-Splice MO (supplemental Fig. S1, 5⬘-AACAGCTCACACAAACACACCTGTA-3⬘). MOs were injected into embryos
at the one cell stage (4 ng of ugdh-ATG MO or 2 ng of ugdhSplice MO). Valve morphology was visualized by fluorescence
microscopy on a Zeiss dissecting microscope. Representative
digital images were captured at 48 h post-fertilization (hpf). For
JOURNAL OF BIOLOGICAL CHEMISTRY
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cardiac phenotype rescue experiments, in vitro transcribed
mRNA encoding UGDH wild type or R141C or E416D mutants
was injected (10 g/ml, 1 nl/embryo) concurrently with Ugdh
MOs (4 ng/embryo) at the one-cell stage. Cardiac edema was
evaluated and quantified at 55 hpf.
Hyaluronan Detection—To confirm functional Ugdh knockdown in embryos, we stained for hyaluronan on paraffin sections as described previously (33). Serum-free medium of
HEK293 cells expressing a neurocan-alkaline phosphatase
fusion protein was a generous gift from Uwe Rauch (University
of Lund).
Generation and Purification of UGDH Point Mutants—Point
mutants of human UGDH were generated from the wild-type
constructs, UGDH-pET28a (for protein purification) or
UGDH-pCS2 (for RNA injections in zebrafish), using the
QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
CA) according to the manufacturer’s protocol. The sequences
were verified by the Genomics Core at the University of
Nebraska-Lincoln. Point mutants were expressed in Escherichia coli strain Rosetta2(DE3)pLysS (EMD Biosciences, Inc.,
San Diego, CA) and purified as N-terminal His6 fusions as previously described (23). Following nickel affinity chromatography, the proteins were dialyzed against 0.1 M sodium phosphate, pH 7.4, and 1 mM DTT. All protein was stored at a
concentration of 10 mg/ml.
Enzymatic Activity Measurement and Kinetic Characterizations—Activity of the point mutants was assayed by monitoring the change in absorbance at 340 nm that accompanies
reduction of NAD⫹ to NADH as reported previously (23). The
R141C and E416D mutants exhibited saturable kinetics.
Michaelis constants Km and Vmax, for UDP-glucose and NAD⫹,
were determined independently by holding [NAD⫹] constant
and varying [UDP-glucose] from 0 to 2 mM. Similarly, NAD⫹
measurements were made by holding [UDP-glucose] constant
and varying [NAD⫹] from 0 to 2 mM. Specific activities were
calculated from absorbance values using the molar extinction
coefficient for NADH of 6220 M⫺1 cm⫺1. Triplicate determinations for each concentration increment were plotted with
PRISM (GraphPad Software, Inc., San Diego, CA). Km and Vmax
were calculated by fitting the data to the Michaelis-Menten
equation and assuming a single binding site/subunit for substrate and cofactor. Activity loss of wild-type and each mutant
enzyme species was measured in aliquots removed at regular
time points until no further activity was detectable. Each aliquot was assayed for 1 min with saturating cofactor and substrate. Specific activity was fitted to a semi-log plot following an
initial lag period to calculate enzyme half-life. Statistical values
were determined from these data by Student’s unpaired twotailed t test.
Molecular Mass Determination—Oligomeric state of the apo
enzyme was determined by size exclusion chromatography as
previously described (23). Each sample was precleared by centrifugation prior to loading. To determine the effect of substrate
and cofactor inclusion on oligomeric state, purified recombinant UGDH wild type and point mutants were individually
loaded on a Superdex 200 HR 10/300 column (GE Healthcare)
using a 250-l loop and separated by FPLC in 1⫻ PBS in the
presence of 1 mM UDP-glucose and 5 mM NAD⫹ at a flow rate
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of 0.5 ml/min. Substrate and cofactor were included in each
250-l load sample at the same final concentrations. Because of
the interference from cofactor in UV absorbance readings from
the column fractions of enzyme complexes, the protein content
of these samples was measured at 595 nm upon the addition of
Bradford reagent. The standards used were: thyroglobulin, 699
kDa; ferritin, 440 kDa; albumin, 67 kDa; ␤ lactoglobulin, 35
kDa; and RNase A, 13.7 kDa. Resolution was sufficient to calculate molecular masses unambiguously in multiples of 57 kDa
(the calculated molecular mass of monomeric His-tagged
UGDH).
Protein Stability Determination—Purified recombinant
UGDH wild type and point mutants were analyzed using a
modified version of the Thermofluor stability assay as
described by Ericsson et al. (34). Solutions of the wild-type and
mutant apo enzymes (⬇5 g of protein in all cases, except
I331N, which required 45 g) were prepared in 1⫻ PBS containing Sypro Orange dye (Invitrogen; 1:500 dilution). Samples
containing substrate and cofactor were prepared in the same
manner with UDP-glucose, and NAD⫹ was added to a final
concentration of 1 mM each. All samples were handled on ice
throughout the preparation and transferred to an iCycler MyiQ
Thermocycler (Bio-Rad) for analysis. The assay protocol was
executed with the block initially cooled to 4 °C. After the addition of samples, the temperature was raised over a period of 76
min from 4 to 79 °C in 0.5 °C increments. The change in fluorescence was monitored for each sample at excitation and emission levels of 490 and 575 nm, respectively. Transitions representing the melting temperature, Tm, were obtained from the
derivative of fluorescence with respect to temperature for at
least 8 –12 replicates and plotted as the means ⫾ S.D.

RESULTS
Embryonic Localization of UGDH in the Developing Mouse
Heart—It was previously shown that ugdh is required for heart
valve formation in zebrafish embryogenesis (11) and is critical
for gastrulation in mice, which arrest at embryonic day 9.5
when its function is disrupted (15). We first examined Ugdh
distribution in mouse embryos, specifically to address its localization in cardiac development. At embryonic day 11.5, strong
expression of Ugdh was observed in the endocardial cushions
located within the AV canal (Fig. 2A). Both the endothelial cells
covering the cushions and the mesenchymal cells within the
cushions stained positive for Ugdh expression. At embryonic
day 12.5, Ugdh mRNA was present in the endocardial cushions
of the AV canal, in the dorsal mesenchymal protrusion and in
the outflow tract cushions (Fig. 2, B and C). At E14.5, specific
expression of Ugdh was observed in the valve leaflets located in
the AV canal (Fig. 2D), which eventually become the leaflets of
the mitral and tricuspid valves. Ugdh expression was not detectable in myocardium, which was visualized by staining for cardiac troponin I (Tnni3) (Fig. 2, E–H).
Functional Examination of UGDH R141C and E416D Variants in Zebrafish—To examine the effects of the single nucleotide polymorphisms identified in the candidate screen of congenital heart disease sufferers, we used a transgenic zebrafish
model in which the endogenous expression of Ugdh was
knocked down by antisense MO injection. In addition to a preVOLUME 287 • NUMBER 39 • SEPTEMBER 21, 2012
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FIGURE 2. Detection of Ugdh during mouse heart development illustrates
localization of expression at sites of endocardial cushion formation preceding valve morphogenesis. Mouse embryos at embryonic days 11.5, 12.5,
and 14.5 were paraformaldehyde-fixed, agarose-embedded, and serially sectioned, followed by in situ hybridization with probes for Ugdh (A–D) and cardiac troponin I (cTnI, E–H). Representative light microscopic images are
shown at the level of the atrioventricular canal (AVC; A, B, D–F, and H) or the
cardiac outflow tract (OFT; C and G). Asterisks indicate the cushions in the AVC
(A and B) or outflow tract (C). The arrows in D indicate the valve leaflets. ra,
right atrium; la, left atrium; rv, right ventricle; lv, left ventricle; lsh, left sinus
horn.

viously published ugdh-ATG MO, we designed and characterized a new ugdh-Splice MO that efficiently affected splicing of
the endogenous ugdh mRNA (supplemental Fig. S1). To assess
the functional consequence of ugdh MO injection on Ugdh
activity in the embryo, we stained the embryos for hyaluronan,
which is a key molecular fate for the UDP-glucuronate product
of UGDH. We observed reduced hyaluronan accumulation in
multiple tissues, including the heart, in embryos injected with
the ugdh MOs relative to uninjected embryos (Fig. 3, A and B).
Next, we used a transgenic zebrafish line in which a GFP
reporter is expressed under an endothelial cell-specific promoter (Tg(Tie2:eGFP)). Use of this model facilitates the visualization of cardiac valve defects because GFP-positive endothelial cells normally cluster in a ring at the AV boundary
beginning at 43 hpf when valve formation initiates. As expected
from previously reported data (11), injection of MOs targeting
ugdh in zebrafish embryos at the single cell stage eliminated
endocardial ring formation (Fig. 3, C and D). We were able to
restore endocardial ring formation by coinjecting the ugdh
MOs with mRNA encoding wild-type human UGDH (Fig. 3E).
However, coinjection of UGDH R141C (Fig. 3F) or UGDH
E416D (not shown) transcripts with the MOs failed to rescue
the loss of endothelial clustering efficiently, suggesting that
both polymorphisms conferred mutations to the UGDH
enzyme that severely compromised its activity in vivo.
Embryos were further examined for cardiac morphogenesis
as reflected in the presence of edema when the absence of endocardial ring formation failed to constrict the heart tube sufficiently for directional fluid flow. Cardiac edema was observed
in ⬎65% of embryos that had been injected with ugdh antisense
MOs (Fig. 3G). Nearly all edema was eliminated by coinjection
of wild-type human UGDH mRNA. However, consistent with
the notion that functional defects are conferred by the UGDH
R141C and E416D polymorphisms, coinjection of mRNA
encoding either of these variants failed to rescue cardiac edema
completely.
In Vitro Characterization of Purified UGDH R141C, E416D,
and I331N (Jekyll)—To characterize the molecular defects in
UGDH R141C and E416D variants more thoroughly and compare them with a previously reported defect, UGDH I331N,
SEPTEMBER 21, 2012 • VOLUME 287 • NUMBER 39

FIGURE 3. Morphological defects in valve development and cardiac
edema associated with UGDH deficiency are reversed by the addition of
wild type but not mutant human UGDH transcripts. Tg(Tie2:EGFP)s849
zebrafish were injected with control (wild type, wt) or antisense Ugdh MOs
(ugdh MO, 4 ng) and imaged at 48 hpf on a fluorescence dissecting microscope. A and B, hyaluronan accumulation was visualized in embryonic sections from control (A) and MO-injected (B) fish with a specific hyaluronanbinding protein coupled to alkaline phosphatase. n, notochord; h, heart.
C–F, images are focused on the AV boundary. The endocardial ring is clearly
visible in wild-type (arrowheads in C) but not ugdh MO fish (D). Coinjection of wt
UGDH mRNA with ugdh MO restored formation of the endocardial ring (E). However, coinjection of ugdh MO and UGDH mutant R141C did not rescue endocardial ring formation (F). G, zebrafish embryos were injected with ugdh MO at the
single cell stage and were evaluated for cardiac edema at 48 hpf. As indicated, the
ability of UGDH wt mRNA to rescue the cardiac morphogenesis defects inflicted
by ugdh MO upon coinjection was assayed and compared with embryos coinjected with UGDH R141C or E416D mRNA (values ⫾ S.E.). *, p ⬍ 0.05.

that prevented valve development in zebrafish, we generated
and expressed each variant with an N-terminal six-histidine
fusion for affinity purification as we have described (23, 29).
JOURNAL OF BIOLOGICAL CHEMISTRY
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TABLE 1
Summary of wild-type and mutant UGDH kinetic constants
NADⴙ

UDP-Glucose
Enzyme

Vmax

Wild-type
R141C
E416D
I331N

0.79 ⫾ 0.02
0.45 ⫾ 0.01a
1.34 ⫾ 0.01a
NDb

mol/min/mg

a
b
c

Km
M

9.19 ⫾ 0.70
4.73 ⫾ 0.24c
13.18 ⫾ 0.42c
ND

Vmax
mol/min/mg

0.92 ⫾ 0.02
0.36 ⫾ 0.01a
1.44 ⫾ 0.03a
ND

Km
M

415 ⫾ 27
172 ⫾ 23c
586 ⫾ 31c
ND

p ⬍ 0.0001 relative to wild type.
ND, not detectable.
p ⬍ 0.001 relative to wild type.

The constructs encoding UGDH R141C and E416D mutants
expressed abundant soluble recombinant protein in E. coli, and
each enzyme form was purified to homogeneity by nickel affinity chromatography. Typical yields were similar for wild type
and both of these mutants, suggesting that neither mutation
intrinsically reduced gene expression or solubility. However,
the UGDH I331N construct yielded significantly reduced quantities of purified protein that was highly unstable even at 4 °C.
Substrate dependence of the enzyme reaction converting UDPglucose to UDP-glucuronate was not saturable for this mutant,
which had minimal detectable activity. However, kinetics for
the other two mutants were saturable, and these measurements
were used to calculate Michaelis-Menten constants (summarized in Table 1). The R141C mutant Vmax was only ⬇40% of the
maximum value for wild-type UGDH, which may partially
explain its human phenotype but exhibited slightly lower Km
for both cofactor and substrate. In contrast, E416D had ⬇40%
higher Vmax and moderately increased Km values relative to the
wild-type enzyme.
Half-life of Wild-type and Mutant UGDH—The differences
in activity of the recombinant mutant enzymes were relatively
nominal considering the magnitude of the phenotype conferred
in vivo by a heterozygous mixture of wild-type and mutant
UGDH enzyme species. Thus, we postulated that the effects on
intrinsic activity could be mediated either by different conditions than those in which we assayed (i.e., intracellular) and/or
that the mutations influenced the stability of the functional
enzyme. To test the latter point, we incubated UGDH wild type,
R141C, and E416D individually at 37 °C and measured activity
over time. The heterozygous condition was simulated in this
experiment by pre-equilibrating a 1:1 mixture of wild-type
UGDH with each mutant at 4 °C, followed by the activity time
course at 37 °C.
UGDH R141C activity was, as expected, ⬇40% of wild type at
time 0 (not shown). To calculate the rate of activity loss independently of the initial value, activities at all time points were
normalized to the 0-h average value (Fig. 4A). This mutant was
highly unstable at 37 °C, with a t1⁄2 of 10.5 ⫾ 0.8 h, compared
with the t1⁄2 of 56.4 ⫾ 6.2 h measured for the wild-type enzyme
(p ⫽ 0.005). The results of this assay further showed that the
mixture of wild type and R141C had a t1⁄2 of 30.3 ⫾ 2.6 h (p ⫽
0.009 relative to wild type), intermediate between the activities
measured in the pure protein solutions. Thus, the R141C
mutant was capable of dramatically destabilizing activity of the
wild-type enzyme in a physiologically relevant time frame.
UGDH E416D activity was, also as expected, slightly higher
than wild type at time 0 (not shown), but it nonetheless lost
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FIGURE 4. Time-dependent activity of wild-type UGDH and point
mutants. Individual purified proteins or a 1:1 mixture of wild-type and
mutant protein as indicated in the legend were equilibrated overnight at 4 °C.
The samples were then placed at 37 °C. At the indicated time points, activity
was assayed by the addition of the enzyme to phosphate buffer containing
saturation concentrations of NAD⫹ and UDP-glucose. The values plotted are
the means ⫾ S.D. for triplicate determinations. For several points, the symbols
obscure the error bars. Absolute turnover was measured as the change in
NADH absorbance at 340 nm in a 1-min assay for comparisons of wild type
with R141C (A) or E416D (B). Absorbance values were normalized to the value
at time 0 to illustrate the rate of activity loss.

activity somewhat more rapidly than wild type (Fig. 4B, t1⁄2 ⫽
41.8 ⫾ 5.7 h, p ⫽ 0.040). The activity of the 1:1 mixture at 0 h,
following its overnight incubation at 4 °C, was also diminished
more rapidly. This suggests that the interaction of wild-type
UGDH with E416D gave rise to an inactive protein population,
with t1⁄2 for the mixture of 37.8 ⫾ 6.6 h (p ⫽ 0.046 relative to wild
type).
Structural Integrity and Intrinsic Stability of Mutant UGDH—
Our lab and others have previously shown that mammalian
UGDH is active as a hexamer (23, 25, 35), and several of our
previously characterized active site mutants show dissociation
to an exclusively dimeric form with dramatic reduction in Vmax
or increased Km. Therefore, we compared the quaternary structure of the R141C, E416D, and I331N mutants with that of
wild-type UGDH by gel filtration chromatography. The wildtype protein eluted with peaks at molecular masses of ⬇360 and
⬇120 kDa, corresponding to a hexamer and a dimer, respectively, of the ⬇57-kDa UGDH monomers (Fig. 5A, solid black
trace), in which the hexamer was clearly the dominant peak.
The elution profiles of both the E416D (Fig. 5B) and R141C (Fig.
5C) mutant enzymes were split in a hexamer-dimer equilibrium. In the case of E416D, the dimeric species accounted for
⬇40% of the absorbance (⬇60% dimer), whereas R141C
appeared to be ⬇80% dimeric. The I331N mutant was almost
exclusively dimeric, with ⬇10% of the absorbance attributable
VOLUME 287 • NUMBER 39 • SEPTEMBER 21, 2012
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FIGURE 5. Hexameric assembly of wild-type and mutant UGDH is sensitive to the presence of substrate and cofactor. Purified wild-type and mutant
UGDH was fractionated by gel filtration FPLC in the absence or presence of NAD⫹ (5 mM) and UDP-glucose (1 mM). Absorbance was monitored at 280 and 595
nm, respectively. Size determination of each peak was made by comparison with molecular weight standards. Representative traces are plotted for wild-type
UGDH (A), E416D (B), R141C (C), and I331N (D). On each plot, the apo-enzyme trace (in black) is superimposed on its holo-enzyme complement (in gray) for
comparison of quaternary structure.

to a peak potentially corresponding to monomeric enzyme.
Consistent with its previously noted instability, the total magnitude of the eluted peaks for I331N UGDH was reduced
10-fold relative to the wild type and other mutants (Fig. 5D).
Interestingly, including saturating levels of NAD⫹ and UDPglucose in the loaded protein and the column running buffer
induced a complete shift of the wild-type UGDH elution profile
to that of the hexamer (Fig. 5A, dotted gray trace). The same
phenomenon was observed for the E416D mutant (Fig. 5B) and,
to a lesser extent, the R141C mutant (Fig. 5C). Such a shift did
not occur appreciably upon substrate and cofactor addition to
I331N. Thus, it appeared that the formation of a holoenzyme
ternary complex stabilized the hexameric quaternary assembly
of the enzyme, and the extent of hexameric association was
somewhat related to the level of stability of the wild type and
each mutant as observed in the activity assays (Fig. 4).
To examine the intrinsic stability of UGDH and its point
mutants in the presence and absence of its substrate and cofactor, we used a thermally sensitive fluorescence assay. Consistent with a previous report using this method (34), the observed
melting temperature (Tm) was ⬇50 °C for the apoenzyme form
of wild-type UGDH and increased to ⬇65 °C when NAD⫹ and
UDP-glucose were added to the reaction mixture (Table 2 and
Fig. 6). Similar results were obtained for the E416D mutant.
Although an increase in Tm with substrate and cofactor addition was observed for both of the other mutants as well, the
apoenzyme form of the R141C mutant was denatured with a Tm
several degrees lower than that of wild type, and the increase in
Tm was only ⬇8 °C. This effect was even more dramatic for the
I331N mutant, which had a Tm of ⬇40 °C for the apoenzyme
and ⬇46 °C for the ternary complex. These results are consistent with greater overall thermal stability of the hexameric form
SEPTEMBER 21, 2012 • VOLUME 287 • NUMBER 39

TABLE 2
Summary of wild type and mutant UGDH melting temperatures
The ternary complex mixture includes 1 mM NAD⫹ and 1 mM UDP-glucose.
Tm

a
a

Enzyme

Apo

Ternary

Wild-type
E416D
I331N
R141C

49.5 ⫾ 0.3
50.7 ⫾ 0.2
40.8 ⫾ 2.7a
46.2 ⫾ 1.0

64.8 ⫾ 0.2
63.5 ⫾ 0.2
46.0 ⫾ 1.4b
55.0 ⫾ 1.0b

p ⬍ 0.001 relative to wild-type apoenzyme.
p ⬍ 0.001 relative to wild-type holoenzyme.

of UGDH and reflect the differences observed in the stability of
the respective mutants.

DISCUSSION
UGDH is an enzyme that has been cloned and characterized
from many diverse species and implicated in zebrafish heart
development for over 10 years. To our knowledge, this is the
first report of a characterization of mutations to UGDH occurring in a population of human patients with congenital heart
valve defects. In this study, we localized expression of UGDH to
a critical region of the developing mouse heart and followed its
timed increase and subsequent decrease over the normal time
frame for cardiac valve formation. We further demonstrated
that the patient mutations R141C and E416D cannot rescue
valve development or cardiac edema resulting from UGDH
deletion in the zebrafish model. A detailed characterization of
the structural and functional features of the mutant enzymes
revealed modest alterations in the intrinsic activity of the
enzyme that may translate to reduced function at cellular levels
of substrate and cofactor. However, the most dramatic impact
of the mutations on enzyme function appeared to derive from
the striking destabilization of intrinsic thermal stability that
leads to accelerated loss of activity in physiological conditions.
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Importantly, we demonstrated that the presence of the mutant
forms in a 1:1 ratio with wild-type UGDH, representative of the
heterozygous genotype found in all patients with the polymorphisms, promotes a loss of wild-type UGDH activity as well.
UGDH was first identified as a cardiac valve initiation factor
in zebrafish by isolating the gene disruption that was present in
the zebrafish valve mutant jekyll (11). The lesion was found to
be a single nucleotide substitution from A to T that generated
an ATC to AAC codon change. The amino acid change, published as isoleucine to aspartate, is actually an isoleucine to
asparagine mutation at a position that is highly conserved
across numerous species including humans. The substitution

FIGURE 6. UGDH is thermally stabilized by the addition of substrate and
cofactor, but protein stability is compromised by mutations that occur at
the dimer interface. Purified wild-type UGDH and point mutants were thermally denatured in 0.5 °C increments from 4 to 79 °C in the presence of Sypro
Orange. The change in fluorescence with respect to temperature was used to
calculate a melting point (Tm) for each enzyme species in the absence (white
bars) or presence (gray bars) of 1 mM UDP-glucose and 1 mM NAD⫹. The
means ⫾ S.D. are plotted for the Tm of each enzyme. ***, p ⬍ 0.001; in addition, p ⬍ 0.001 for apo versus holo forms of wild-type, E416D, and R141C
UGDH.

had not been previously characterized in the context of the
enzyme structure. We found the I331N mutant to be highly
unstable and poorly expressed, with further impairment in quaternary structure assembly and virtually undetectable residual
activity. These properties are a direct consequence of perturbations to the local environment of the Ile-331 residue by the
substitution (Fig. 7A). This residue is located in a strongly
hydrophobic core motif and is well packed among several other
nonpolar amino acid side chains. Significant disruption to this
stable, well conserved motif would be expected by the introduction of a hydrophilic amino acid side chain in any one of these
positions, so this accounts for the strong effect of the asparagine
substitution on UGDH stability.
Examination of Glu-416 in the context of the UGDH ternary
complex structure (Fig. 7B) illustrates its role in indirect positioning of the UDP-glucose substrate via two water molecules
in collaboration with the side chain of lysine 339. The backbone
of the loop containing Lys-339 is stabilized by hydrogen bonding to Glu-416. Thus, effects of the E416D substitution were
predicted to include decreased binding of UDP-glucose. In fact,
the Km for UDP-glucose is increased by ⬇50% (Table 1). This
relatively modest reduction in apparent affinity for substrate in
the context of enzymatic turnover is also accompanied by a
significant acceleration in the loss of activity at 37 °C (Fig. 4)
and destabilization of the hexameric quaternary assembly in
the absence of substrate and cofactor (Fig. 5), although the
intrinsic thermal stability is not compromised (Fig. 6). We previously found that the K339A substitution increased Km for
UDP-glucose by ⬎150-fold, and yielded an exclusively dimeric
apoenzyme. The more direct role in UDP-glucose coordination
through interaction with both phosphate groups accounts for
the significant difference in Km between the K339A and E416D
mutants. The observed effect on the hexamer-dimer equilibrium is consistent with a link between active site integrity, substrate and cofactor binding capacity, and hexameric assembly,
which ultimately determines enzyme stability. Reduced stabil-

FIGURE 7. Local interactions in UGDH near sites of clinically relevant mutations. A, the core of UGDH is depicted transparently with key hydrophobic
residues shown as wires. Ile-331 is shown in ball and stick conformation colored gold. B, the substrate UDP-glucose is represented in ball and stick form colored
by heteroatom. Glu-416 is also represented as ball and stick directly hydrogen-bonded (black lines) to a water (W1) and the backbone of a loop. Glu-416 is
involved in positioning UDP-glucose in its binding pocket by coordinating two waters (W1 and W2) and Lys-339, depicted in wire form. C, surface filling model
of the dimer interface is shown in green and blue. Each dimer pair is colored a separate color such that the interface is between two dimers. Arg-141 is
represented in ball and stick form hydrogen-bonded (black lines) to a water (W1) as well as the backbone of helix 1 (H1).

32714 JOURNAL OF BIOLOGICAL CHEMISTRY

VOLUME 287 • NUMBER 39 • SEPTEMBER 21, 2012

Mutations in Human UDP-glucose Dehydrogenase
ity of the E416D hexamer results in propagation of instability to
the wild-type enzyme, as observed in a simulated heterozygous
condition (Fig. 4), so this is a likely explanation for the effects of
this mutation on cardiac valve morphogenesis, as discussed
below.
Comparison of results from the R141C mutant is consistent
with this explanation. Arg-141 is located at the interface
between dimeric units of the hexamer (Fig. 1) and maintains a
hydrogen bond network that stabilizes a helix-loop-␤ motif
critical to the dimer-dimer association (Fig. 7C). Substitution of
this residue with a cysteine eliminates these contacts and
releases the helix from its tight association, which would be
expected to disrupt the quaternary structure to an exclusively
dimeric form as was shown in Fig. 5. The reduced stability of the
dimer is associated with a reduction in enzymatic activity
(Table 1), destabilization of the mutant in both a homozygous
and a heterozygous reaction mixture (Fig. 4), and significantly
reduced thermal stability in the absence or presence of ternary
complex components (Fig. 6). The reductions in activity and
stability are probable underlying causes of the phenotype associated with this missense mutation in human patients.
The relatively modest differences in enzymatic activity of the
R141C and E416D mutants is not entirely surprising because
bacterial homologues are only found as dimers (24). However,
the inability to form normal complexes may nonetheless have
dramatic impact on the stability of wild-type heterohexamers
with either R141C or E416D and/or on the potential for allosteric regulation within a cellular context. This is particularly
intriguing because the addition of substrate and cofactor at saturating levels can fully restore the hexameric structure.
Although hexameric structure is not critical for achieving wildtype maximum reaction velocity if optimal conditions are provided (29), studies of the nucleotide sugar dehydrogenase family member GDP-mannose dehydrogenase (36) suggest that
hexameric structure provides the capacity for allosteric regulation and cooperativity with respect to substrate use. Thus, the
effects on quaternary assembly, particularly the ability to
restore and maintain a stable ternary complex within a physiological range of available substrate and cofactor, could translate
to significant differences in the net enzymatic activity in developmentally critical phases.
UGDH is the only enzyme that provides UDP-glucuronate,
which is an essential precursor for hyaluronan synthesis, initiation of all proteoglycan synthesis, and elongation of the glycosaminoglycan chains that comprise proteoglycans. In mice,
UGDH gene disruption is embryonically lethal (15), and in
zebrafish Ugdh inactivation results in cardiac valve defects (11).
UGDH and HAS2 gene disruption have identical phenotypes,
and cardiac tissue explant studies, in which AV septum formation can be restored by exogenous hyaluronan, the product of
the HAS2 gene, demonstrate that UGDH must function at a
high level during heart formation to supply precursors for hyaluronan production (9). It has been further shown in the Xenopus model system that UGDH expression directly dictates the
production capacity for hyaluronan during development (12).
Our results show that UGDH is expressed at a very high level
specifically in the region of the developing valves throughout
valve development (Fig. 2). The introduction of transcripts
SEPTEMBER 21, 2012 • VOLUME 287 • NUMBER 39

encoding either the R141C or E416D mutant form of UGDH
was insufficient to support valve formation or prevent cardiac
edema (Fig. 3), which clearly illustrates a significant level of
impairment resulting from these missense mutations in vivo.
Based on the infrequency with which UGDH mutations have
been reported, it is likely that most UGDH polymorphisms do
not yield viable embryos. In support of the extreme phenotypic
distress conferred by such lesions, only the heterozygous and
not the homozygous expression of R141C and E416D is
observed in the population study (30). The characterizations we
described above point toward a significant loss of enzyme stability and resultant reduction in UDP-glucuronate production
below the levels that are required to sustain hyaluronan synthesis while the cardiac cushions are forming. Cardiac cushions are
largely the result of rapid hyaluronan extrusion and accumulation between the layers of the myocardium and endocardium
beginning at embryonic day 9.5. Their formation produces tissue protrusions that are invaded by endocardial cells, which
delaminate because of epithelial to mesenchymal transition.
Their absence prevents epithelial to mesenchymal transition
for cell migration into the AV septum, which is needed for
subsequent valve differentiation. Because this process necessitates rapid deposition of large quantities of hyaluronan, UGDH
function is critical at this time, and even modest reductions in
its function are clearly disruptive. Screening families for these
alleles may assist in the prediction of cardiac valve defects and
offer therapeutic targets.
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Supplementary Figure 1. Injection of ugdh splice-MO affects endogenous ugdh mRNA
spicing.
(A) Schematic presentation of genomic ugdh region around exon 3 and 4. The ugdh spliceMO targets the proposed splice donor site of exon 3 (red line). Position of PCR primers are
indicated by arrows. (B) Schematic presentation when correct splicing has occurred. Primers
p1 and p2 will generate a 235 base pair (bp) PCR fragment. (C) Agarose gel showing PCR
fragments after reverse transcriptase using primer combinations indicated. Reverse
transcriptase (RT) PCR was performed on RNA isolated from 2 day old embryos uninjected
or injected with the ugdh splice MO. –RT, negative control without reverse transcriptase; red
arrow, unspliced PCR fragment; blue arrow, correct spliced PCR fragment.

